CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Tetracycline +2 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02576652
NCT02576652Phase 4Completed
CompareCT.gov

Bone Histomorphometry of the Proximal Femur in Denosumab-treated Subjects Undergoing Total Hip Replacement

Amgen·interventional·Posted Oct 15, 2015·Updated Apr 26, 2019

In Brief

A Phase 4 clinical trial evaluating Tetracycline, Demeclocycline, and 1 other intervention for Osteoporosis. Completed, enrolled 6 participants across 2 sites.

Detailed Summary

The primary objective of this study is to determine the incidence of modeling-based bone formation in the femoral neck in participants who have received denosumab and are undergoing total hip replacement (THR).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedOct 15, 2015
Enrollment StartDec 22, 2015
Primary CompletionDec 18, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.7 years ago

Interventions

Tetracyclineother

Treatment during cycle 1 consists of a total oral dose of 1000 mg of tetracycline daily for a total of 3 days.

Demeclocyclineother

Treatment during cycle 2 consists of a total oral dose of 600 mg of demeclocycline daily for 3 days.

Total Hip Replacementprocedure

Participants entering this study were prescheduled to undergo elective THR due to osteoarthritis. Surgery was to be performed according to local standard of care. During THR a fragment of femoral bone was acquired for histomorphometry evaluation.